Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas

医学 危险系数 比例危险模型 四分位间距 内科学 置信区间 肿瘤科 结直肠癌 队列 阶段(地层学) 切除缘 生存分析 化疗 癌症 外科 切除术 古生物学 生物
作者
Rui Mao,Kan Li,Jianqiang Cai,Sheng Luo,Megan C. Turner,Dan G. Blazer,Hong Zhao
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
卷期号:274 (2): e126-e133 被引量:25
标识
DOI:10.1097/sla.0000000000003562
摘要

Objective: The aim of this study was to determine whether adjuvant chemotherapy (AC) provides a survival benefit in patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas (CRNECs) following resection. Background: There is little evidence to support the association between use of AC and improved overall survival (OS) in patients with CRNECs. Methods: Patients with resected non-metastatic CRNECs were identified in the National Cancer Database (2004–2014). Inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups. Results: A total of 806 patients diagnosed between 2004 and 2014 met the study entry criteria. Of these, 394 patients (48.9%) received AC. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer for AC versus observation [57.4 (interquartile range, IQR, 14.8–153.8) vs 38.2 (IQR, 10.4–125.4) months; P = 0.007]. In IPTW-adjusted Cox proportional hazards regression analysis, AC was associated with a significant OS benefit [hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.64–0.84; P < 0.001]. The results were consistent across subgroups stratified by pathologic T stage, pathologic N stage, and surgical margin status. Subgroup analysis according to tumor location demonstrated improved OS in the adjuvant therapy cohort among patients with left-sided neuroendocrine carcinomas (HR, 0.55; 95% CI, 0.44–0.68), but not in those with right-sided disease (HR, 0.89; 95% CI, 0.74–1.07). Conclusions: Patients with nonmetastatic CRNECs may derive survival benefit from AC. These findings support current guidelines recommending AC in patients with poorly differentiated neuroendocrine carcinomas in the colon and rectum. Efforts in education and adherence to national guidelines for NECs are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
昱昱完成签到 ,获得积分10
2秒前
yunna_ning完成签到,获得积分10
4秒前
白眉苏发布了新的文献求助10
4秒前
橙子完成签到 ,获得积分10
6秒前
珍惜完成签到,获得积分10
7秒前
夏木南生完成签到 ,获得积分10
17秒前
荔枝完成签到 ,获得积分10
22秒前
24秒前
yutang完成签到 ,获得积分10
27秒前
三磷酸腺苷完成签到 ,获得积分10
30秒前
喏晨完成签到 ,获得积分10
36秒前
redamancy完成签到 ,获得积分10
37秒前
shw完成签到,获得积分10
37秒前
葶ting完成签到 ,获得积分10
38秒前
39秒前
abc完成签到 ,获得积分10
44秒前
Yang应助虞无声采纳,获得10
48秒前
zcg完成签到,获得积分10
52秒前
闲人不贤完成签到,获得积分10
52秒前
完美采梦完成签到 ,获得积分10
54秒前
何世通完成签到 ,获得积分10
59秒前
后浪完成签到 ,获得积分10
1分钟前
我住隔壁我姓王完成签到,获得积分10
1分钟前
纯真的雁山完成签到,获得积分10
1分钟前
笑点低的如凡完成签到,获得积分10
1分钟前
《子非鱼》完成签到,获得积分10
1分钟前
务实的绝悟完成签到,获得积分10
1分钟前
Betty完成签到 ,获得积分10
1分钟前
xmhxpz完成签到,获得积分10
1分钟前
gYang完成签到,获得积分10
1分钟前
guan完成签到,获得积分10
1分钟前
Li完成签到 ,获得积分10
1分钟前
独特的忆彤完成签到 ,获得积分10
1分钟前
liuxuan发布了新的文献求助10
1分钟前
Owen应助南城雨落采纳,获得10
1分钟前
yi完成签到 ,获得积分10
1分钟前
xyzlancet完成签到,获得积分10
1分钟前
酷炫的红牛完成签到,获得积分10
1分钟前
1分钟前
聆琳完成签到 ,获得积分10
1分钟前
高分求助中
LNG地下式貯槽指針(JGA指-107) 1000
LNG地上式貯槽指針 (JGA指 ; 108) 1000
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 900
QMS18Ed2 | process management. 2nd ed 600
LNG as a marine fuel—Safety and Operational Guidelines - Bunkering 560
Exploring Mitochondrial Autophagy Dysregulation in Osteosarcoma: Its Implications for Prognosis and Targeted Therapy 526
Full waveform acoustic data processing 500
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2937339
求助须知:如何正确求助?哪些是违规求助? 2593965
关于积分的说明 6986099
捐赠科研通 2237324
什么是DOI,文献DOI怎么找? 1188188
版权声明 589991
科研通“疑难数据库(出版商)”最低求助积分说明 581651